Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 05, 2022 08:00 ET | Source: Cogent Biosciences, Inc.

Cogent Biosciences to Host Investor Webcast to Discuss Updated Clinical Data at ASH from the Ongoing Phase 2 APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis

WALTHAM, Mass. and BOULDER, Colo., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
November 28, 2022 16:15 ET | Source: Cogent Biosciences, Inc.

Cogent Biosciences Appoints Rachael Easton, MD, Ph.D., VP, Head of Clinical Development

WALTHAM, Mass. and BOULDER, Colo., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
November 14, 2022 07:00 ET | Source: Cogent Biosciences, Inc.

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2022 Financial Results

Phase 3 PEAK trial initiated comparing bezuclastinib + sunitinib vs. sunitinib alone in second line gastrointestinal stromal tumor (GIST) patients; initial safety and pharmacokinetic data from lead-in...
November 09, 2022 08:00 ET | Source: Cogent Biosciences, Inc.

Cogent Biosciences Announces Participation at Upcoming Investor Conferences

WALTHAM, Mass. and BOULDER, Colo., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
November 03, 2022 09:05 ET | Source: Cogent Biosciences, Inc.

Cogent Biosciences Announces Bezuclastinib Presentations at the 64th Annual American Society of Hematology (ASH) Meeting

WALTHAM, Mass. and BOULDER, Colo., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
October 26, 2022 07:00 ET | Source: Cogent Biosciences, Inc.

Cogent Biosciences to Showcase Precision Therapy Pipeline at the EORTC-NCI-AACR Annual Meeting

WALTHAM, Mass. and BOULDER, Colo., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
August 09, 2022 07:00 ET | Source: Cogent Biosciences, Inc.

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2022 Financial Results

On-track to present additional data from Phase 2 APEX trial by the end of 2022 Initial data from Phase 2 SUMMIT trial & lead-in data from Phase 3 PEAK trial planned for 1H23 Ended 2Q 2022...
June 16, 2022 16:01 ET | Source: Cogent Biosciences, Inc.

Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

CAMBRIDGE, Mass. and BOULDER, Colo., June 16, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
June 13, 2022 21:48 ET | Source: Cogent Biosciences, Inc.

Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock and Pre-funded Warrants

CAMBRIDGE, Mass. and BOULDER, Colo., June 13, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
June 13, 2022 06:00 ET | Source: Cogent Biosciences, Inc.

Cogent Biosciences Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass. and BOULDER, Colo., June 13, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...